1,721,137 research outputs found
Novel Approaches to Reducing the Risk of Variceal Hemorrhage
No full textComplications of advanced liver disease occur at the moment of clinical significant portal hypertension. Nitric oxide (NO) dysfunction and fibrosis play an important role in the pathophysiology of PH, but other mechanisms are also involved. Non-selective beta blockers (NSBB) stay the cornerstone in the primary and secondary prevention of variceal bleeding, but their safety in advanced cirrhosis has been recently debated and new drugs are under investigation. Transjugular intrahepatic portosystemic shunt and balloon tamponade are the standard therapy in case of refractory variceal bleeding, but both interventions have drawbacks. Key Message: Transelastography under certain conditions and the presence of collateral circulation on imaging allow to rule-in CSPH, which makes patients open at risk for variceal hemorrhage. FXR agonists are intrahepatic NO donors; they reduce fibrosis and prevent bacterial translocation, which make them promising drugs for the treatment of PH. NSBB should be used with caution in patients with refractory ascites and certainly in those with hepatorenal syndrome. Preliminary clinical data suggest that simvastatin and enoxaparin improve the prognosis of patients with cirrhosis. Finally, covered esophageal metallic stents are safer and more effective than balloon tamponade in the case of refactory variceal bleeding.sponsorship: Frederik Nevens received a consultancy fee from Intercept Pharmaceuticals. (Intercept Pharmaceuticals)status: Publishe
Supplementary_Material – Supplemental material for Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
No full textSupplemental material, Supplementary_Material for Drug holiday in patients with polycystic liver disease treated with somatostatin analogues by René M. M. van Aerts, Marieke Kolkman, Wietske Kievit, Tom J. G. Gevers, Frederik Nevens and Joost P. H. Drenth in Therapeutic Advances in Gastroenterology</p
Ethyl Glucuronide in Hair Is an Accurate Biomarker of Chronic Excessive Alcohol Use in Patients With Alcoholic Cirrhosis
No full textsponsorship: Jef Verbeek received a research grant from the Vlaamse Vereniging voor Gastroenterologie (Flemish Association of Gastroenterology). David Cassiman and Frederik Nevens are fundamental clinical researchers of the FWO Vlaanderen. (Vlaamse Vereniging voor Gastroenterologie (Flemish Association of Gastroenterology))status: Publishe
MARS_supplementary_table_and_figures – Supplemental material for Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity
No full textSupplemental material, MARS_supplementary_table_and_figures for Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity by Rafael Bañares, Luis Ibáñez-Samaniego, Josep María Torner, Marco Pavesi, Carmen Olmedo, María Vega Catalina, Agustín Albillos, Fin Stolze Larsen, Frederik Nevens, Tarek Hassanein, Harmuth Schmidt, Uwe Heeman, Rajiv Jalan, Richard Moreau and Vicente Arroyo in Therapeutic Advances in Gastroenterology</p
Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
No full textIsabelle Colle - Consulting: Promethera; Grant/Research Support: abbvie; Patent Held/Filed: Trombogenics; Speaking and Teaching: BMS
Christophe Moreno - Consulting: Abbvie, Janssen, Gilead, BMS, MSD; Grant/Research Support: Janssen, Gilead, Roche, Astellas, Abbvie
Frederik Nevens - Consulting: MSD, CAF, Intercept, Gore, BMS, Abbvie, Novartis, Durect, Janssens-Cilag, Ono Pharma, Promethera Biosciences, Gilead; Grant/Research Support: Ferring, Roche, Astellas, Novartis, Janssen-Cilag, Abbvie, Gilea
Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
No full textIsabelle Colle - Consulting: Promethera; Grant/Research Support: abbvie; Patent Held/Filed: Trombogenics; Speaking and Teaching: BMS
Christophe Moreno - Consulting: Abbvie, Janssen, Gilead, BMS, MSD; Grant/Research Support: Janssen, Gilead, Roche, Astellas, Abbvie
Frederik Nevens - Consulting: MSD, CAF, Intercept, Gore, BMS, Abbvie, Novartis, Durect, Janssens-Cilag, Ono Pharma, Promethera Biosciences, Gilead; Grant/Research Support: Ferring, Roche, Astellas, Novartis, Janssen-Cilag, Abbvie, Gilea
Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials
No full textPolycystic liver disease is associated with impaired health-related quality of life (HRQL). Somatostatin analogues reduce hepatomegaly in polycystic liver disease.sponsorship: Joost P.H. Drenth has received previous grant support from Ipsen and Novartis. Marie C Hogan has received previous grant support from Novartis. Frederik Nevens has received previous grant support from Ipsen. (Ipsen, Novartis)status: Publishe
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
- …
